Contact us

Thank you for your interest in Garg Law PLLC.

Our commitment to understanding your regulatory questions and business goals, and helping you achieve results starts here.

If you are looking for representation on a new matter, please fill out the form below to request a free consultation. The form enables us to conduct a preliminary check for potential conflicts of interest and to determine if we can proceed with the free consultation.

By completing this form, you agree that you have viewed our Terms & Conditions and Privacy Policy. Please note that the material contained on this Website is provided solely for informational purposes and does not constitute legal advice. The information is not guaranteed to be correct, complete, or current. Prior results also do not guarantee a similar outcome, as each case must be evaluated on its own merits. Please also note that the Information on the Website is not intended to create, and receipt or viewing does not constitute, or offer to create, an attorney-client relationship between you and Garg Law.

The US Food and Drug Administration FDA on Samples for Food Testing Used as Evidence for the Release of Certain Fish and Fishery Products

February 13, 2024

FDA Updates
Dear Food Product Stakeholder, The US Food and Drug Administration FDA Recommendations for Collecting Representative Samples for Food Testing Used as Evidence for Release of Certain Fish and Fishery Products Subject to Detention Without Physical Examination DWPE and Removal of a Foreign Manufacturers Goods from DWPE

This draft guidance aims to provide recommendations for collecting samples of seafood products that are under DWPE due to potential adulteration from pathogens, unlawful animal drugs, scombrotoxin (histamine), or decomposition. The FDA guidance is designed to assist foreign manufacturers and processors in submitting evidence to the FDA to request removal of their products from DWPE.

It addresses industry challenges in proving the safety of their seafood products under DWPE and intends to clarify the FDA’s stance on the removal of the appearance of adulteration, while offering tools to support importation. Public comments on the draft guidance are invited within 60 days of its publication in the Federal Register, either electronically to www.regulations.gov under docket number FDA-2023-D-5303 or in writing to the Dockets Management Staff in Rockville, MD.

____________________________________________________________

 

The U.S. Food and Drug Administration (FDA) today issued draft guidance for industry titled “Recommendations for Collecting Representative Samples for Food Testing Used as Evidence for Release of Certain Fish and Fishery Products Subject to Detention Without Physical Examination (DWPE) and Removal of a Foreign Manufacturer’s Goods from DWPE.” The draft guidance provides recommendations for collecting representative samples for seafood products subject to Detention Without Physical Examination (DWPE) under an Import Alert because of the appearance of adulteration caused by pathogens, unlawful animal drugs, scombrotoxin (histamine), and/or decomposition.

The draft guidance, once finalized, will help foreign manufacturers and other processors of seafood products subject to DWPE submit evidence to the FDA to support a request to have their products removed from DWPE.

This guidance addresses the concern that industry may experience challenges in supporting their arguments about the safety of seafood products subject to DWPE.

The intent of this draft guidance is to clarify the FDA’s thinking on when the appearance of adulteration may be removed, while giving industry the tools it needs to help support importation.

To Submit Comments

Comments on the draft guidance should be submitted within 60 days after publication in the Federal Register. Submit electronic comments to www.regulations.gov to docket number FDA-2023-D-5303. Written comments should be submitted to the Dockets Management Staff (HFA-305), Food and Drug Administration, 5630 Fishers Lane, Room 1061, Rockville, MD 20852. All written comments should identify the docket number FDA-2023-D-5303

Additional Information:

Request a Consultation

★★★★★

Working with Shelly on various new product launches over the last couple of years has been seamless. Quick and clear guidance is always what we get.
R.G. Client
I've been working with Shelly and her team at Garg law for a little while now and they are fantastic! Very responsive, professional and they certainly get things done. Extremely satisfied with their service and highly recommend.
Mike H. Client
Ms Garg helped my company navigate an FDA import issue. She achieved an excellent result, was very responsive and professional, and managed to keep the project within budget. She is a stellar attorney.
Dr. Sastry Client
I have been using Shelly Garg as FDA Counsel for 10+ years, since she was at another international law firm. While we continued to use the previous firm she was at (mainly due to the process required to change firms), we realized the quality of counsel was not the same. We have since been using Garg Law and the ease of use and trust in the knowledge was back instantly. Shelly has the skills to help me understand the regulations (by translating into layman's terms) and risks in a manner that is specific to my business. She is also extremely timely in her responses which is critical when we have a deadline mandated by the FDA. Many other attorneys cite the regulations which l've already read, but need further counsel. In my opinion, this demonstrates Shelly's in-depth knowledge of the regulations, how they pertain to the law, and how they are applicable IRL. Shelly's personable approach and pleasant manner in communication makes it very easy to have been work with her and have productive discussions on the best next steps. She truly has a passion iternational for all things FDA and I've learned so much from her.
Claire P. Client

News & Insights

Get the latest news on FDA regulatory delivered straight to your inbox.